ArticleThoracic cancer2022

Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.

Sheng-Yuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.